EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

Julian Kögel iD, Sandra Schuh iD, Julia Welzel iD, Michael Sticherling iD, Lukas Sollfrank iD, Carola Berking iD, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer iD, Martin Valentin Vitus, Tilo Biedermann und 4 weitere

International Journal of Dermatology · 2026-12 · 65 (12) · 2524-2531

DOI: 10.1111/ijd.70422 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, online erschienen am 17.04.2026. Verfasst von Julian Kögel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Psoriasis, Dermatitis, Exfoliative, Biological Products, Antirheumatic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erythrodermic psoriasis (EP) is a rare but severe condition. Because of its low prevalence, there are no standardized treatment recommendations for EP. Specific EP guidelines are outdated, prioritizing conventional disease‐modifying antirheumatic drugs (cDMARDs) and tumor necrosis factor‐alpha (TNF‐α) inhibitors.

Methods

We conducted a multicenter retrospective chart analysis in five academic centers in Bavaria, Germany (Augsburg, Erlangen, LMU Munich, TU Munich, Regensburg). Patients diagnosed with EP between 2019 and 2024 who received systemic treatment were included in the study.

Results

A total of 29 patients were included. cDMARDs were initiated in 8 patients (27.6%). Biologics were used in 21 patients (72.4%). Psoriasis Area and Severity Index (PASI) decreased from 31.9 to 10.8 across all therapies ( p < 0.001). PASI 75 was achieved with methotrexate (1), cyclosporine (1), fumarates (1), infliximab (1), ustekinumab (2), ixekizumab (1), secukinumab (2), risankizumab (4), and guselkumab (1). PASI 100 was achieved with infliximab (1), ustekinumab (1), and risankizumab (2). Adverse events occurred most frequently in the cDMARDs group.

Conclusion

There is a wide variety of treatment approaches. Standardized guidelines are needed. Biologic therapies, especially interleukin (IL)17 and IL23‐inhibitors, showed favorable outcomes in this cohort and warrant prospective evaluation. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDermatitis, ExfoliativeBiological ProductsAntirheumatic AgentsDermatologic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultTreatment OutcomeSeverity of Illness IndexGermanyAntibodies, Monoclonal, HumanizedCyclosporine

Stichwörter der Autor:innen

Germanyantirheumatic drugsbiologicscomorbiditydrugserythrodermafumaratesoutcomepsoriasistreatment

Substanzen

Biological ProductsAntirheumatic AgentsDermatologic AgentsAntibodies, Monoclonal, HumanizedCyclosporine

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Department of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany.
  • Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
  • Department of Dermatology and Allergology, Ludwig-Maximilian-University, Munich, Germany.
  • Dr. Phillip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA.
  • Department of Dermatology and Allergology, Technical University Munich, Munich, Germany.

ORCID-Profile: Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Felix Lauffer, Susanne Bauer, Dennis Niebel

Zitieren

APA

Kögel, J., Schuh, S., Welzel, J., Sticherling, M., Sollfrank, L., Berking, C., Pumnea, T., Glatzel, V., French, L., Lauffer, F., Vitus, M. V., Biedermann, T., Bauer, S., Spindler, M., Berneburg, M., & Niebel, D. (2026). Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study. International Journal of Dermatology, 65(12), 2524-2531. https://doi.org/10.1111/ijd.70422

Vancouver

Kögel J, Schuh S, Welzel J, Sticherling M, Sollfrank L, Berking C, et al. Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study. International Journal of Dermatology. 2026;65(12):2524-2531. doi:10.1111/ijd.70422

BibTeX
@article{Kgel2026,
  author = {Kögel, Julian and Schuh, Sandra and Welzel, Julia and Sticherling, Michael and Sollfrank, Lukas and Berking, Carola and Pumnea, Teodora and Glatzel, Valerie and French, Lars and Lauffer, Felix and Vitus, Martin Valentin and Biedermann, Tilo and Bauer, Susanne and Spindler, Michael and Berneburg, Mark and Niebel, Dennis},
  title = {Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {12},
  pages = {2524--2531},
  doi = {10.1111/ijd.70422}
}
Kostenlos starten →